Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for use

Bibliography

• JACOBI J, FRASER GL, COURSIN DB et al.: Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Grit. Care Med. (2002) 30:119–141.
   PubMed Web of Science ®Google Scholar
• ••Guidelines for the use of sedatives andanalgesics in the critically ill.
   Google Scholar
• AYD FJ Jr: Haloperidol: twenty years' clinical experience. J Gun. Psychiatry (1978) 39:807–814.
   Google Scholar
• SETTLE ED Jr, AYD FJ Jr: Haloperidol: a quarter century of experience. J. Clin. Psychiatry (1983) 44:440–448.
   PubMed Web of Science ®Google Scholar
• RIKER RR, FRASER GL, COX PM: Continuous infusion of haloperidol controls agitation in critically ill patients. Grit. Care Med. (1994) 22:433–440.
   PubMed Web of Science ®Google Scholar
• SANDERS KM, MURRAY GB, CASSEM NH: High dose intravenous haloperidol for agitated delirium in a cardiac patient on intra-aortic balloon pump. j Gun. Pychopharmacol (1991) 11:146–147.
   Web of Science ®Google Scholar
• TAYLOR DM: Antipsychotics and QT prolongation. Acta Psychiatr. Scand. (2003) 107:85–95.
   PubMed Web of Science ®Google Scholar
• ••A thorough review on the effects ofantipsychotics on the QTc interval.
   Google Scholar
• DOUGLAS PH, BLOCK PC: Corrected QT interval prolongation associated with intravenous haloperidol in acute coronary syndromes. Cathet. Cardiovasc. Intervent. (2000) 50:352–355.
   PubMed Web of Science ®Google Scholar
• GLASSMAN AH, BIGGER JT: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J Psychiatry (2001) 158:1774–1782.
   PubMed Web of Science ®Google Scholar
• HATTA K, TAKAHASHI T, NAKAMURA H et al.: The association between intravenous haloperidol and prolonged QT interval. j Gun. Psychopharmacol (2001) 21:257–261.
   Web of Science ®Google Scholar
• CZEKALLA J, KOLLACK-WALKER S, BEASLEY CM: Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J. Clin. Psychiatry (2001) 62\(Suppl. 2):35–40.
   Google Scholar
• TISDALE JE, RASTY S, PADHI D, SHARMA ND, ROSMAN H: The effect of haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of torsade de pointes.j Gun. Pharmacol (2001) 41:1310–1318.
   Google Scholar
• ZEE-CHENG C, MUELLER CE, SEIFERT CF et al.: Haloperidol and torsade de pointes. Ann. Intern. Med. (1985) 102:418.
   PubMed Web of Science ®Google Scholar
• ••The first report of torsade de pointesassociated with haloperidol administration.
   Google Scholar
• SENEFF MG, MATHEWS RA: Use of haloperidol infusions to control delirium in critically ill adults. Ann. Pharmacother. (1995) 29:690–693.
   PubMed Web of Science ®Google Scholar
• METZGER E, FRIEDMAN R: Prolongation of the corrected QT and torsade de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J. Clin. Psychopharmacol (1993) 13:128–132.
   PubMed Web of Science ®Google Scholar
• ••The first report of torsade de pointesassociated with intravenous haloperidol.
   Google Scholar
• HUNT N, STERN TA: The association between intravenous haloperidol and torsade de pointes: three cases and a literature review. Psychosomatics (1995) 36:541–549.
   PubMed Web of Science ®Google Scholar
• •An older, but still significant, review of torsade de pointes associated with haloperidol.
   Google Scholar
• O'BRIEN JM, ROCKWOOD RP, SUH KI: Haloperidol-induced torsade de pointes. Ann. Pharmacother. (1999) 33:1046–1050.
   PubMed Web of Science ®Google Scholar
• SHARMA ND, ROSMAN HS, PADHI ID, TISDALE JE: Torsade de pointes associated with intravenous haloperidol in critically ill patients. Am. J. CardioL (1998) 81:238–240.
   PubMed Web of Science ®Google Scholar
• ••A case-control study that helps delineaterisk factors for the development of torsade de pointes associated with haloperidol.
   Google Scholar
• DI SALVO TG, O'GARA PT: Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin. CardioL (1995) 18:285–290.
   PubMed Web of Science ®Google Scholar
• WILT JL, MINNEMA AIVI, JOHNSON RF, ROSENBLUM AM: Torsade de pointes associated with the use of intravenous haloperidol. Ann. Intern. Med. (1993) 119:391–394.
   PubMed Web of Science ®Google Scholar
• PERRAULT LP, DENAULT A, CARRIER M, CARTIER R, BELISLE S: Torsade de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. Can. J Anesth. (2000) 47:251–254.
   PubMed Web of Science ®Google Scholar
• LAWRENCE KR, NASRAWAY SA: Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy (1997) 17:531–537.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the topic withguidelines for use of haloperidol in the critically ill.
   Google Scholar
• MODESTIN J, KRAPF R, BOKER W: A fatality during haloperidol treatment: mechanism of sudden death. Am. J Psychiatry (1981) 138:1616–1617.
   PubMed Web of Science ®Google Scholar
• VELTKAMP R: [Sudden death following a single oral administration of haloperidol]. Ned. Tzjdschr. Geneeskd. (2002) 146:1301. Dutch.
   Google Scholar
• GREENE YM, MCDONALD VM, DUGGAN J, COOPER R: Ventricular ectopy associated with low-dose intravenous haloperidol and electroconvulsive therapy. ECT (2000) 16:309–311.
   PubMed Web of Science ®Google Scholar
• DESERTENNE F: [Ventricular tachycardiawith 2 variable opposing foci]. Arch. Mal. Coeur (1966) 59:263-272. French.
   Google Scholar
• •The seminal paper on torsade de pointes.
   Google Scholar
• JACKMAN WM, FRIDAY KJ, ANDERSON JL et al.: The long QT syndromes: a critical review, new clinical observations, and a unifying hypothesis. Prog Cardiovasc. Dis. (1988) 31:115–172.
   PubMed Web of Science ®Google Scholar
• LAASKO M, ABERG A, SAVOLA J et aL: Diseases and drugs causing prolongation of the QT interval. Am. J CardioL (1987) 59:862–865.
   PubMed Web of Science ®Google Scholar
• ••A helpful review on the causes ofQT prolongation.
   Google Scholar
• MARTIN TG: Advanced life support in the poisoned patient (TOX ACLS). In: Clinical Toxicology. Ford MD et al. (Eds), WB Saunders, Philadelphia (200 0:12–20.
   Google Scholar
• KEMPER AJ, DUNLAP R, PIETRO DA: Thioridazine-induced torsade de pointes. Successful therapy with isoproterenol. JAMA (1983) 249:2931–2934.
   Google Scholar
• FOWLER NO, MCCALL D, CHOU TC, HOLMES JC, HANENSON IB: Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am. J CardioL (1976) 37:223–230.
   PubMed Web of Science ®Google Scholar
• OGATA N, NARAHASHI T: Block of sodium channels by psychotropic drugs in single guinea-pig cardiac myocytes. Br. J. PharmacoL (1989) 97:905–913.
   PubMed Web of Science ®Google Scholar
• GOULD RJ, MURPHY KM, REYNOLDS IJ, SNYDER SH: Calcium channel blockade: possible explanation for thioridazine's peripheral side effects. Am. J Psychiatry (1984) 141:352–357.
   PubMed Web of Science ®Google Scholar
• FLAIM SF, BRANNAN MD, SWIGART SC et al.: Neuroleptic drugs attenuate calcium influx and tension development in rabbit thoracic aorta: effects of pimozide, penfluridol, chlorpromazine, and haloperidol. Proc. NatL Acad. Sci. USA (1985) 82:1237–1241.
   PubMed Web of Science ®Google Scholar
• HENDERSON RA, LANES, HENRY JA:Life-threatening ventricular arrhythmia (torsade de pointes) after haloperidol overdose. Hum. Exp. ToxicoL (1991) 10:59–62.
   PubMed Web of Science ®Google Scholar
• KRIWISKY M, PERRY GY, TARCHITSKY D, GUTMAN Y, KISHON Y: Haloperidol-induced torsade de pointes. Chest (1990) 98:482–484.
   PubMed Web of Science ®Google Scholar
• JACKSON T, DITMANSON L, BRENDAN P: Torsade de pointes and low-dose oral haloperidol. Arch. Intern. Med. (1997) 157:2013–2015.
   PubMed Web of Science ®Google Scholar
• CARR AA, MEYER DR: Synthesis of terfenadine. Arzneimittelfirschung (1982) 32:1157–1159.
   PubMed Web of Science ®Google Scholar
• HONIG PK, WORTHAM DC, ZAMANI K, CONNER DP, MULLIN JC, CANTILENA LR: Terfenadine-ketoconazole interaction. Pharmacokinetic and elecrocardiographic consequences. JAMA (1993) 269:1513–1518.
   Google Scholar
• MATHEWS DR, MCNUTT B, OKERHOLM R, FLICKER M, MCBRIDE G: Torsade de pointes occurring in association with terfenadine use. JAMA (1991) 266:2375–2376.
   PubMed Web of Science ®Google Scholar
• WOOSLEY RL, CHEN Y, FREIMAN JP, GILLIS RA: Mechanism of the cardiotoxic actions of terfenadine. JAMA (1993) 269:1532–1536.
   PubMed Web of Science ®Google Scholar
• MICHALETS EL, SMITH LK, VAN TASSEL ED: Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann. Pharmacother. (1998) 32:761–765.
   PubMed Web of Science ®Google Scholar
• TESAR GE, MURRAY GB, CASEEM NH: Use of high-dose intravenous haloperidol in the treatment of agitated cardiac patients. Clin. PsychopharmacoL (1985) 5:344–347.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ F, HOLMES VF, ADAMS F, KAVANAUGH JJ: Treatment of severe, refractory agitation with a haloperidol drip. J Clin. Psychiatry (1988) 49:239–241.
   PubMed Web of Science ®Google Scholar
• AMERICAN HEART ASSOCIATION: Guidelines for Cardiopulmonary Resuscitation Emergency Cardiovascular Care. Circulation (2000) 102(Suppl. I):I-1-I–384.
   Google Scholar